Tristetraprolin Regulates the Expression of the Human Inducible Nitric-Oxide Synthase Gene

Marcel Fechir, Katrin Linker, Andrea Pautz, Thomas Hubrich, Ulrich Förstermann, Fernando Rodriguez-Pascual, and Hartmut Kleinert

Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany (M.F., K.L., A.P., T.H., U.F., H.K.); and Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Madrid, Spain (F.R.-P.)

Received October 28, 2004; accepted March 18, 2005

ABSTRACT

The expression of human inducible NO synthase (iNOS) is regulated both by transcriptional and post-transcriptional mechanisms. Stabilization of mRNAs often depends on activation of p38 mitogen-activated protein kinase (p38 MAPK). In human DLD-1 cells, inhibition of p38 MAPK by the compound 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB203580) or by overexpression of a dominant-negative p38 MAPK resulted in a reduction of human iNOS mRNA and protein expression, whereas human iNOS promoter activity was not affected. An important RNA binding protein regulated by the p38 MAPK pathway and involved in the regulation of the stability of several mRNAs is tristetraprolin. Regulation of human inducible nitric-oxide synthase (iNOS) expression takes place in large part as a result of post-transcriptional mechanisms modulating mRNA stability (Rodriguez-Pascual et al., 2000; Kleinert et al., 2004). AU-rich elements (AREs) are critical cis-acting elements in the 3′-untranslated regions (3′-UTRs) of many cytokine, transcription factor, and proto-oncogene mRNAs and are targets for trans-acting proteins regulating mRNA stability and translation (Bevilacqua et al., 2003). The human iNOS mRNA contains five such AREs in the 3′-UTR. In transfection experiments with human A549 or DLD-1 cells, the 3′-UTR of the human iNOS mRNA destabilizes the mRNA of a heterologous reporter gene (Rodriguez-Pascual et al., 2000).

A number of ARE binding proteins have been identified that can interact with AU- and U-rich regions. These include AUF-1 (Zhang et al., 1993), the ELAV protein family members [the most important is HuR, (Brennan and Steitz, 2001)], the KH-type splicing regulatory protein [KSRP (Chen et al., 2001)], and tristetraprolin (Carballo et al., 1998). HuR is known to stabilize several inducible ARE-containing mRNAs (Brennan and Steitz, 2001). Gel retardation experiments with human A549 or DLD-1 cells consistently resulted in enhanced or reduced iNOS expression by modulating iNOS-mRNA stability. In UV cross-linking experiments, recombinant tristetraprolin did not interact with the human iNOS mRNA. However, communoprecipitation experiments showed interaction of tristetraprolin with the KH-type splicing regulatory protein (KSRP), which is known to recruit mRNAs containing AU-rich elements to the exosome for degradation. This tristetraprolin–KSRP interaction was enhanced by cytokines and reduced by SB203580 treatment. We conclude that tristetraprolin positively regulates human iNOS expression by enhancing the stability of human iNOS mRNA. Because tristetraprolin does not directly bind to the human iNOS mRNA but interacts with KSRP, tristetraprolin is likely to stabilize iNOS mRNA by capturing the KSRP-exosome complex.
experiments showed high-affinity interaction of HuR with the human iNOS 3'-UTR (Rodriguez-Pascual et al., 2000). Therefore, enhancing or reducing HuR expression in human DLD-1 cells resulted in up- or down-regulation, respectively, of cytokine-induced iNOS expression (Rodriguez-Pascual et al., 2000).

In contrast to HuR, tristetraprolin, a zinc finger protein, has been shown to destabilize the mRNAs of several immediate-early genes, such as c-fos, interleukin (IL) 3, interferon (IFN) γ, tumor necrosis factor (TNF) α, and granulocyte/macrophage colony stimulating factor (Blackshear, 2002). Tristetraprolin–/- mice develop a severe inflammatory phenotype because of an increased expression of pro-inflammatory cytokines such as TNF-α and granulocyte/macrophage colony stimulating factor. This enhanced cytokine expression is a consequence of the loss of the negative regulation at the post-transcriptional level (Carballo et al., 1998).

In line with these data, Chen et al. (2001) showed tristetraprolin-dependent ARE-mRNA degradation activity of the human exosome (a complex of exonucleases that catalyzes the 3' → 5' decay pathway of mRNAs. By interaction with different ARE-binding proteins, such as KSRP and tristetraprolin, the exosome is recruited to these mRNAs to degrade them subsequently (Chen et al., 2001).

Analyses of the mechanisms of stabilization of ARE-containing mRNAs revealed the critical involvement of the p38 mitogen-activated protein kinase (p38 MAPK) (Kracht and Saklatvala, 2002). Pharmacological inhibition of p38 MAPKα and -β (by SB203580) or inhibition of these enzymes by overexpression of dominant-negative isoforms resulted in enhanced degradation of different ARE-containing mRNAs, such as the cyclooxygenase-2 mRNA (Ridley et al., 1998) and the TNF-α mRNA (Mahtani et al., 2001). It is interesting that in rat primary mesangial cells, p38 MAPKα and β regulate iNOS expression in opposite directions (Lui et al., 2004).

The exact pathway by which p38 MAPK stabilizes ARE-containing mRNAs is not known. p38 MAPK was found either directly or via the MAPK-activated protein kinase 2 (MAPKAPK-2/MK2) to control the expression and posttranslational modification of tristetraprolin (Carballo et al., 2001; Tchen et al., 2004), suggesting that, at least in part, the p38 MAPK-mediated stabilization of ARE-mRNAs may work by modulating tristetraprolin expression/activity.

In the current study, we first analyzed the effect of p38 MAPK inhibition on iNOS expression. Our experiments showed no influence of the p38 MAPK inhibitor SB203580 on cytokine-induced human iNOS promoter activity, but did show inhibition of cytokine-induced iNOS mRNA and protein expression. Overexpression of a dominant-negative isoform of murine p38 MAPKα also decreased cytokine-induced iNOS expression. To further elucidate the molecular mechanism of p38 MAPK-mediated iNOS mRNA regulation, we analyzed the involvement of tristetraprolin in this post-transcriptional regulation. The data show that the cytokines inducing human iNOS expression also enhanced tristetraprolin expression. In addition, SB203580 incubation reduced the cytokine-mediated enhancement of tristetraprolin expression. Overexpression of tristetraprolin resulted in a marked increase in iNOS expression, which was based on mRNA stabilization. UV cross-link experiments failed to show any interaction of tristetraprolin with the human iNOS mRNA. However, coimmunoprecipitation experiments showed cytokine-enhanced interactions of tristetraprolin with KSRP, which is known to be essential for the degradation of ARE-containing mRNAs by the exosome. Therefore, tristetraprolin seems to be involved indirectly in regulation of human iNOS expression by interaction with KSRP. By capturing the KSRP-exosome complex, tristetraprolin seems to dislodge this complex from the iNOS mRNA. This results in enhanced mRNA stability and thereby enhanced iNOS expression.

Materials and Methods

**Reagents.** Trypsin, glutamine, and pyruvate solutions, phenylmethylsulfonyl fluoride, leupeptin, aprotinin, agarose, isopropyl β-D-thiogalactoside, polyvinylpyrrolidone, tRNA, bovine serum albumin, actinomycin D, protein A-agarose beads, monoclonal anti-β-tubulin and monoclonal anti-FLAG antibodies, and horseradish peroxidase-coupled anti-rabbit and anti-mouse IgG were purchased from Sigma (Deisenhofen, Germany). Monoclonal anti-iNOS antibodies were obtained from R&D systems, Wiesbaden, Germany. Isotopes were obtained from PerkinElmer Life and Analytical Sciences (Köln, Germany). Restriction enzymes, Taq polymerase, Klenow DNA polymerase, dNTPs, oligo-dT primer, Ficoll 400, pGEX-2T and glutathione-agarose affinity beads were purchased from Amersham Bioscience (Freiburg, Germany). The monoclonal anti-β-actin antibodies were obtained from New England Biolabs (Heidelberg, Germany). RNase A, RNase T1, DNase I, T3 and T7 RNA polymerase, FuGene and complete EDTA-free protease inhibitor cocktail tablets were obtained from Roche Diagnostics (Mannheim, Germany). The Quantitect Probe RT-PCR Kit was from QIAGEN (Hilden, Germany). All oligonucleotides and dual-labeled probes were from MWG Biotech (Ebersberg, Germany). Human IFN-γ, IL-1β, and TNF-α were obtained from Strathagen (Heidelberg, Germany). FCS, DMEM, and RPMI 1640 medium were purchased from PAN-Systems (Nürnberg, Germany). G-418 and SB203580 were purchased from Calbiochem (Bad Soden, Germany). Zeocin, pZeosV2(−), and pCDNA3 were purchased from Invitrogen ( Groningen, The Netherlands). pCR-Script was from Stratagene (Heidelberg, Germany), and psiRNA-H11-GF-Pzeo was obtained from InvivoGen (San Diego, CA). The Bradford reagent mix for determination of protein concentration was obtained from Bio-Rad (Munich, Germany). The dual-luciferase reporter assay system and passive lysis buffer were purchased from Promega (Heidelberg, Germany). The polyclonal anti-tristetraprolin antibody was a kind gift of Dr. William Rigby (Department of Medicine, Dartmouth Medical School, Lebanon, NH), the polyclonal anti-KSRP antibody was kind gift of Dr. Ching-Yi Chen (Department of Biochemistry and Molecular Genetics, University of Alabama, Birmingham, AL), and the monoclonal anti-KSRP antibody was a kind gift of Dr. Douglass L. Black (Howard Hughes Medical Institute, UCLA, Los Angeles, CA).

**Cell Culture, Cytokine Treatment, and RNA Isolation.** Human alveolar epithelial A549/8 cells and human colon carcinoma DLD-1 cells were grown in DMEM with 2 mML-glutamine, penicillin/streptomycin, and 5 or 10% heat-inactivated fetal bovine serum, respectively. Eighteen hours before cytokine activation, cells were washed with phosphate-buffered saline and incubated with DMEM containing 2 mML-glutamine in the absence of serum and phenol red. iNOS expression in DLD-1 cells was induced with a cytokine mixture (CM) containing 100 U/ml IFN-γ, 50 U/ml IL-1β, and 10 ng/ml TNF-α for the corresponding time periods depending on the experiment. In some experiments, cells were treated with SB203580 at various concentrations 1 h before and during cytokine incubation. Afterward, supernatant of the cells (300 μl) was used to measure NOx by the Griess reaction or the Sievers Nitric Oxide Analyzer (ADInstruments, Spechbach, Germany), and cells were processed for RNA isolation by guanidinium thiocyanate/phenol/chloroform.
tristetraprolin expression was calculated. mRNA in the same sample. Then the values of untreated cell sample in each sample were normalized to the C(T) values of GAPDH. The C(T) values for iNOS, luciferase, or tristetraprolin mRNA expression (Livak and Schmittgen, 2001) was used. According to this method, the expression of linearized plasmids pCR-NOS II-human, pCR-β-actin-human, pMcm-GAPDH-human (Witteck et al., 2003), pCR-luc-pGII (Rodríguez-Pascual et al., 2000), and pCR-kTTP were in vitro-transcribed using T3 or T7 RNA polymerase and [α-32P]UTP. To quantify human iNOS, luciferase, and tristetraprolin mRNA levels, RNAse protection experiments were performed as described previously (Rodríguez-Pascual et al., 2000). In all experiments, β-actin- or GAPDH mRNA was also determined for normalization purposes. Densitometric analyses were performed using filmless autoradiographic analysis (Bio-Rad). The protected fragments of iNOS, luciferase, tristetraprolin, β-actin, and GAPDH were 386, 230, 174, 109, and 108 nucleotides, respectively.

Quantitative Reverse Transcription/Polymerase Chain Reaction (qRT-PCR). One-Step RT-PCR was performed with the QuantiTect RT PCR Kit (QIAGEN) in 25-μl reactions in a 96-well spectrofluorometric thermal cycler (iCycler; Bio-Rad). RNA was isolated as described above. For real-time qRT-PCR (RT reaction, 50°C for 30 min, 95°C for 15 min; PCR reaction, 94°C for 15 s, 60°C for 60 s, 40 cycles), the oligonucleotides listed below served as sense and antisense primers and Taqman hybridization probes. Taqman hybridization probes were double-labeled with 6-carboxyfluorescein as reporter fluorophore and 5-carboxytetramethylrhodamine as quencher. All primers and dual-labeled probes (5′-6-carboxyfluorescein, 3′-5-carboxytetramethylrhodamine) were from MWG-Biotech. Fluorescence was monitored at each 60°C step. iNOS: sense, TGCA-GACACTGGGTACTTC; antisense, GTTGGACACGCATACCG-GATG; hybridization probe, TGGCAAGCAGCTCCGGGTG; GAPDH: sense CCGAGTCTTGTCCATCGGTT; antisense, TGGTGATGAGTCTTTCCAGATA; hybridization probe, CTGGACACCA-CAACTGTGTATAC; tristetraprolin: sense, TGGCCATCCGTC-CAACCT; antisense, GCGCCACCTCTTGGACAGGT; hybridization probe, CCCCTGCCGTCAACAGTCTGAGT; luciferase: sense, AAAAAATGCGCGGAGGA; antisense, TTITTCGTCG- GTCAGTGTTC; hybridization probe, TGTGTGGTTGGACAGAG- TACCGAAGGTCCTAC. Each experimental reaction was performed in triplicate. All primer/probes sets had efficiencies of 100% (±10%).

To calculate the relative expression of iNOS, luciferase, or tristetraprolin mRNA in DLD-1- or A549/8 cells, the 2−ΔΔC(T) method (Livak and Schmittgen, 2001) was used. According to this method, the (C(T)) values for iNOS, luciferase, or tristetraprolin mRNA expression in each sample were normalized to the (C(T)) values of GAPDH mRNA in the same sample. Then the values of untreated cell samples were set at 100%, and the percentage of iNOS, luciferase, or tristetraprolin expression was calculated.

Actinomycin D Experiments. To analyze the effects of experimental interventions on the iNOS mRNA stability, cells were incubated as indicated and iNOS expression was induced by cytokines for 6 h. Then, 10 μM actinomycin D was added and RNAs were prepared 0 to 18 h thereafter. Relative iNOS and GAPDH mRNA amounts were determined by qRT-PCR, and iNOS mRNA was normalized to GAPDH mRNA. The relative amount of iNOS mRNA at 0 h actinomycin D time curves were performed by nonlinear regression using Prism 3.0 (GraphPad Software, San Diego, CA).
in RIPA buffer. Beads were washed three times with RIPA buffer, and coimmunoprecipitated proteins were analyzed by Western Blotting.

Purification of GST-TTP Protein. To generate pGEX-HA-hTTP, a bacterial expression plasmid coding for a GST-HA-tristetraprolin fusion protein (GST-TTP), the plasmid pCMV-hTTP-Flag (Lai et al., 1999), kindly provided by Dr. Blackshear) was digested with HindIII. The fragment was purified by gel electrophoresis and cloned into pcR-Script (Stratagene) to generate pCR-HA-hTTP. Then pCR-HA-hTTP was digested with ClaI and EcoRV, and the ends were blunted by treatment with the Klenow enzyme. The fragment was purified by gel electrophoresis and cloned into pGEX-2T (Amersham Biosciences) digested with SmaI. DNA sequences of the clones were determined using the dye-terminator chain termination method with a sequencing kit from Pfizer. Purified GST-TTP fusion protein was prepared using the plasmid pGEX-HA-hTTP as described previously (Rodriguez-Pascual et al., 2000). The yield of the purification procedure was determined by comparison to a bovine serum albumin standard on Coomassie blue-stained SDS-PAGE. The electrophoresis revealed a 63-kDa band corresponding to the fusion protein. The same procedure was used to purify GST protein from Escherichia coli cultures transformed with the plasmid pGEX-2T.

UV Cross-Linking Experiments. cDNAs encoding for subfragments of human iNOS 3'-UTR have been described previously (Rodriguez-Pascual et al., 2000). To obtain the 5'-UTR and coding sequence (cds) of the human iNOS mRNA and the 3'-UTR of the human c-fos mRNA, PCR reactions were performed using the primers N2-SUTR-5P1 (5'-CCCAACATATATAACTTGGTGAACGATCAGC-3') and N2-SUTR-3P1 (5'-CCGCATCTGAGATGCTGTCCTTGGACGAGC-3') or N2-cds-5P1 (5'-CCGGCCGGCTCCAGAGCGCTGACATCTCCA-3'), and hum-fos-AUFL-5P1 (5'-CATGCTGGAGTGTCAGTGTGGG-3') or hum-fos-AUFL-3P1 (5'-CTTGGAGACAAAGGGCAATC-3'), respectively. The PCR fragments were restricted with HindIII or XhoI, and treated with T4 polynucleotide kinase, and cloned in pcR-Script to generate pCR-iNOS-5'-UTR, pCR-iNOS-cds, and pCR-hum-fos-AUFL. To generate radiolabeled iNOS 5'-UTR, cds or 3'-UTR, or human c-fos AUFL sense probes for RNA binding experiments, 0.5 to 1 μg of DNA (linearized plasmids or PCR fragments) were in vitro-transcribed as described above. Radiolabeled transcribed transcripts were analyzed by urea-denaturing electrophoresis to estimate the yield and the specific activity. Incorporated radioactivity in transscripts was usually higher than 80%, and the specific activity ranged from 0.2 to 0.5 Ci/pmol.

For UV cross-linking experiments, radiolabeled iNOS-5'-UTR, -cds, or -3'-UTR RNA and human c-fos-3'-UTR RNA were incubated with 0.6 μg of purified GST fusion protein in a volume of 25 μl in a binding buffer (10 mM HEPES, pH 7.6, 3 mM MgCl₂, 5 mM EDTA, 2 mM dithiothreitol, 5% glycerol, 0.5% Nonidet P-40, 3 mg/ml heparin, and 0.5 mg/ml yeast (RNA) supplemented with 40 mM KCl and RNasin (0.3 U/ml), final) for 20 min at 37°C. Then the probes were irradiated with UV-C light (125 mJ) for 30 min on ice. RNA not protected by protein binding was digested by addition of RNases T1 (20 U/assay) and RNase A (20 μg/assay) for 30 min at 30°C. The reaction was stopped by addition of 6 μl of 5% Laemmli loading buffer (312.5 mM Tris-HCl, pH 6.8, 5 mM EDTA, 15% SDS, 50% glycerin, 0.015% bromphenol blue, and 40 mM dithiothreitol). After denaturation at 80°C for 10 min the samples were separated in 12% SDS polyacrylamide gels, the gels were dried and exposed to X-ray films.

Establishment of Cell Lines Expressing a Sense or Anti-sense Tristetraprolin mRNA, a Dominant-Negative p38 MAPKα, or a Vector-Derived Small Interfering RNA for Down-Regulation of Tristetraprolin Expression. The plasmid pZeo-hTTP-HA-sense or -antisense was generated by cloning a 1000-base pair HindIII fragment from pCMV-hTTP-flq (Lai et al., 1999) containing the cDNA sequence of a HA-tagged tristetraprolin protein in both orientations into pZeoSV2(−) (Invitrogen). DNA sequences of the clones were determined using the dye-terminator chain termination method with a sequencing kit from Pfizer. To generate DLD-1 cells overexpressing a sense or antisense HA-tagged tristetraprolin mRNA, cells were transfected with 5 μg of pZeo-hTTP-HA-sense or -antisense by lipofection with FuGene according to the manufacturer’s recommendations. Stable transfectants were selected with Zeocin (200 μg/ml). As a control, DLD-1 cells stably transfected with the pZeoSV2(−) vector were generated as well (pCDNA3). Pooled populations of cells were characterized for p38AGF-FLAG expression by Western blots using a monoclonal anti-FLAG-antibody and by RT-PCR analyses.

The plasmid psiRNA-hH1-GFPzeo-TTP was generated by cloning a double-stranded oligonucleotide (5'-ACCTACAAAGAGATCGGTTATGTGCTGATCGGATCGTTCAGACATC-3') into the Bbs I sites of psiRNA-hH1-GFPzeo (Invivogen). The DNA sequence of the construct was determined using the dye-terminator chain termination method with a sequencing kit from Pfizer. To generate A549/8 cells stably expressing shRNAs directed against the human tristetraprolin mRNA, cells were transfected with 5 μg of psiRNA-hH1-GFPzeo-TTP by lipofection with FuGene according to the manufacturer’s recommendations. Stable transfectants were selected with Zeocin (200 μg/ml). Because the psiRNA-hH1-GFPzeo vector codes for a GFP-Zeo resistance fusion protein, the Zeocin-resistant cell pools were also selected for GFP expression by fluorescence-activated cell sorting. As a control, A549/8 cells stably transfected with the empty psiRNA-hH1-GFPzeo vector were generated as well.

Statistics. Data represent means ± S.E.M. Statistical differences were determined by factorial analysis of variance followed by Fisher’s protected least-significant-difference test for comparison of multiple means.

Results

Inhibition of p38 MAPK by Compound SB203580 or by Overexpression of a Dominant-Negative p38 MAPKα Markedly Reduces iNOS mRNA and Protein Expression but Has No Effect on Human iNOS Promoter Activity. To test the effect of SB203580-mediated inhibition of p38 MAPK on human iNOS promoter activity and iNOS mRNA expression, we used DLD-1 cells stably transfected with pNOS2(16)Luc, a construct containing the human tristetraprolin mRNA under the control of the human iNOS promoter. Cells were transfected with SB203580 (0 to 10 μM) for 1 h. Then, iNOS expression was induced by a CM (100 U/ml IFN-γ, 10 ng/ml TNF-α, and 50 U/ml IL-1β). After 2 to 48 h, cells were lysed and RNA was purified. To analyze the iNOS and luciferase mRNA expression, quantitative RNase protection experiments were performed using anti-sense probes for human iNOS and luciferase mRNA. For normalization, expression of β-actin mRNA was determined in the same reaction. qRT-PCR experiments were performed
as well as using the primer/probes described under Materials and Methods. For normalization in qRT-PCR experiments, the expression of GAPDH mRNA was determined in a parallel reaction using the same RNA sample. As shown in Fig. 1, no iNOS mRNA (A and C) or protein (D) expression was detected in unstimulated DLD-1 cells. However, in accordance with previous results (Rodriguez-Pascual et al., 2000), basal levels of luciferase mRNA were detected (Fig. 1, B and C). Basal luciferase activity was measured in extracts of these cells (data not shown). Incubation of the cells with CM resulted in marked induction (>50-fold) of iNOS mRNA expression (Fig. 1, A and C). In contrast, luciferase mRNA expression was induced only ~5-fold (Fig. 1, B and C). CM-incubation also resulted in nearly 5-fold enhancement of luciferase activity in extracts of these cells (data not shown). Inhibition of p38 MAPK by SB203580 resulted in marked reduction of the human iNOS mRNA (Fig. 1, A and C), protein expression (Fig. 1D), and iNOS-mediated NO production (Fig. 1E). In contrast, SB203580 influenced neither basal nor cytokine-induced luciferase mRNA expression (Fig. 1, B and C).

There are four different isoforms of p38 MAPK (see Introduction), but only two (p38 MAPKα and -β) are inhibited by SB203580. Because SB203580 inhibited CM-induced iNOS expression in DLD-1 cells and Liu et al. (2004) described opposite effects of p38 MAPKα (stabilizing) and -β (destabilizing) on iNOS expression in rat mesangial cells, we also tested the effect of inhibition of p38 MAPKα by overexpression of a dominant-negative p38 MAPKα isoform. We stably transfected DLD-1 cells with pCS3-FLAG-p38AGF (Winzen et al., 1999), leading to overexpression of a dominant-negative murine p38 MAPKα protein in these cells. As shown in Fig. 1F, stable overexpression of this dominant-negative p38 MAPKα protein resulted in marked inhibition of cytokine-induced iNOS expression in human DLD-1 cells.

Therefore, these data indicate that human iNOS expression depends both on transcriptional and post-transcriptional mechanisms. Furthermore, activation of the p38 MAPK pathway seems to be critically involved in the post-transcriptional regulation of human iNOS expression.

Cytokines Enhance Expression of Tristetraprolin and iNOS in Human DLD-1 Cells. Tristetraprolin has been described as a destabilizing protein for ARE-containing mRNAs (Blackshear, 2002). Recent evidence also suggests that tristetraprolin is involved in the regulation of mRNA stability of ARE-containing mRNAs in response to p38 MAPK (Mahtani et al., 2001; Stockeclin et al., 2004). Therefore, we analyzed the role of tristetraprolin in human iNOS expression. First, we tested the effect of cytokine incubation on tristetraprolin expression in DLD-1 cells. As shown in Fig. 2, cytokine-incubation of DLD-1 cells resulted in enhanced tristetraprolin mRNA (Fig. 2, A and B) and protein expression (Fig. 2C). It is interesting that the time curve of the enhancement of tristetraprolin expression paralleled the time curve of iNOS induction (Rodriguez-Pascual et al., 2000).

Inhibition of p38 MAPK by SB203580 Reduces Cytokine-Induced Tristetraprolin Expression. It has been reported that tristetraprolin expression is regulated by the p38 MAPK pathway (Tchen et al., 2004). Therefore, we analyzed the influence of SB203580-mediated inhibition of p38 MAPK on the cytokine-stimulated tristetraprolin expression. As shown in Fig. 3, SB203580 reduced cytokine-induced tristetraprolin expression.

Biological Role of Tristetraprolin: Overexpression of Sense or Antisense Tristetraprolin mRNA or Down-Regulation of Tristetraprolin Expression by siRNAs. To determine whether tristetraprolin plays a role in the regulation of iNOS gene expression in intact cells, we generated stably transfected DLD-1 cells which constitutively express sense tristetraprolin mRNA (pZeo-hTTPs) or antisense tristetraprolin mRNA (pZeo-hTTPas) under the control of the early SV40 promoter (pZeoSV2 expression plasmid). Pooled cell populations were analyzed for stable integration of the DNA and tristetraprolin expression. As a control, DLD-1 cells stably transfected with the (empty) pZeoSV2 vector were generated as well (pZeo). As shown in Fig. 4A, Western blot experiments revealed enhanced tristetraprolin protein expression in pZeo-hTTPs cells, whereas a decrease of tristetraprolin protein expression was seen in pZeo-hTTPas cells. Overexpression of sense tristetraprolin-cDNA resulted in enhanced cytokine-induced iNOS mRNA expression (Fig.

Fig. 1. Effect of compound SB203580-mediated inhibition of p38 MAPK on human iNOS mRNA and protein expression and human 16-kb iNOS promoter activity. DLD-1 cells stably transfected with pNOS216Luc, a construct containing a 16-kb fragment of the human iNOS promoter in front of a firefly luciferase reporter gene, were preincubated for 18 h in medium without FCS and phenol red. Then the cells were pretreated for 1 h with SB203580 (SB, 0–10 μM). Thereafter, cells were incubated with or without cytokine mixture (CM: 100 U/ml IFN-γ, 10 ng/ml TNF-α, and 50 U/ml IL-1β) in the presence or absence of SB203580 at the concentrations indicated. Total RNA and cytoplasmic proteins were prepared after 6 and 24 h, respectively. A, representative RNase protection experiment to detect iNOS mRNA expression in the stably transfected DLD-1 cells. Experiments were performed using antisense RNA probes for human iNOS- and β-actin mRNA (used for normalization). The positions of the protected luciferase (Luc) and β-actin fragments are indicated. B, representative RNase protection experiment to detect luciferase mRNA expression in the stably transfected DLD-1 cells. Experiments were performed using antisense RNA probes for luciferase- and human β-actin mRNA (used for normalization). The positions of the protected luciferase (Luc) and β-actin fragments are indicated. C, summary of densitometric analyses of nine different gels and four qRT-PCR analyses using RNA isolated from stably transfected DLD-1 cells. Data (means ± S.E.M.) represent relative iNOS- and luciferase (Luc) mRNA levels (**, p < 0.01; ns, not significant versus iNOS or luciferase mRNA levels in cells not treated with SB203580). D, Western blots using monoclonal anti-iNOS- and -actin mRNA (used for normalization). The positions of the protected luciferase (Luc) and β-actin fragments are indicated. C, summary of densitometric analyses of nine different gels and four qRT-PCR analyses using RNA isolated from stably transfected DLD-1 cells. Data (means ± S.E.M.) represent relative iNOS- and luciferase (Luc) mRNA levels (**, p < 0.01; ns, not significant versus iNOS or luciferase mRNA levels in cells not treated with SB203580). D, Western blots using monoclonal anti-iNOS- and -actin antibodies or monoclonal anti-tubulin-antibodies for the detection of iNOS- and β-actin mRNA expression. A, representative Western blot showing similar results. E, analysis of the iNOS-mediated NO production in DLD-1 cells treated with or without 10 μM SB203580 by measurement of nitrite in supernatants of the cells. Cells were preincubated for 18 h in serum-free medium and then pretreated with or without 10 μM SB203580 (SB) for 1 h. Afterward, cells were treated with or without a CM for another 48 h. Columns (means ± S.E.M., n = 10) represent the relative nitrite levels determined (100% corresponds to 407 pmol/ml/48 h; **, p < 0.01 versus CM-treated DLD-1 cells). F, DLD-1 cells stably transfected with pCS3-FLAG-p38AGF (Winzen et al., 1999), a construct coding for a dominant-negative murine p38 MAPKα isoform (p38DN), or the empty plasmid pCDNA3 (Invitrogen), were preincubated for 18 h in medium without FCS and phenol red. Then cells were incubated with or without cytokine mixture (CM). Total RNA was prepared after 6 h. iNOS mRNA and GAPDH mRNA concentrations were determined by qRT-PCR, and iNOS mRNA was normalized to GAPDH mRNA. A summary of six qRT-PCR analyses is shown. Data (means ± S.E.M.) represent relative iNOS mRNA levels (***, p < 0.001; ns, not significant versus CM-treated stably pCDNA3-transfected DLD-1 cells).
Fig. 2. CM enhances tristetraprolin expression in DLD-1 cells. DLD-1 cells were preincubated for 18 h in medium without FCS and phenol red. Then cells were incubated with or without CM for the time periods indicated, and total RNA or cytoplasmic proteins were isolated. A, representative RNase protection experiment detecting tristetraprolin, iNOS, and GAPDH mRNA expression in DLD-1 cells. Experiments were performed using antisense RNA probes for human tristetraprolin, iNOS, and GAPDH mRNA (used for normalization). The positions of the protected tristetraprolin (TTP), iNOS, and GAPDH fragments are indicated. M, molecular weight standard, 4X174-restricted with HindIII; T, tRNA control. B, summary of densitometric analyses of eight different gels similar to A and five different qRT-PCR analyses. Columns (means ± S.E.M.) represent relative tristetraprolin mRNA levels in CM-treated cells compared with control cells (*, p < 0.05; **, p < 0.01; ns, not significant versus control cells). C, Western blot using specific anti-tristetraprolin and anti-β-tubulin antibodies and cytoplasmic extracts from DLD-1 cells. This blot is representative of three other blots showing similar results.
4, B and C). This result was unexpected, because tristetraprolin is generally believed to be an ARE-binding protein leading to mRNA degradation. However, consistent with the results above, reduction of tristetraprolin expression by an antisense approach impaired cytokine-induced iNOS mRNA expression (Fig. 4, D and E). In addition, cytokine-induced, iNOS-dependent NO production was enhanced by tristetraprolin overexpression in DLD-1-pZeo-hTTPas cells and reduced by tristetraprolin down-regulation in DLD-1-pZeo-hTTPas cells (Fig. 4F).

To support this unexpected result of tristetraprolin-mediated enhanced level of iNOS expression, we aimed to down-regulate tristetraprolin expression in a different cell line using siRNAs. Therefore, we generated A549/8 cells stably transfected with psiRNA-hH1-GFPzeo-TTP. In these cells, siRNAs containing a hairpin structure (shRNAs) were generated, which were directed against the human tristetraprolin mRNA. As shown in Fig. 5, A and B, tristetraprolin expression was reduced in A549/8-psiRNA-hH1-GFPzeo-TTP cells (siTTP) on RNA and protein level compared with A549/8 cell stably transfected with the empty vector psiRNA-hH1-GFPzeo (GFP). As shown above for the DLD-1-pZeo-hTTPas cells, siRNA-mediated down-regulation of tristetraprolin expression resulted in a marked reduction of cytokine-induced iNOS mRNA expression also in A549/8 cells (Fig. 5C). Therefore, tristetraprolin seems to be positively involved in the regulation of cytokine-induced iNOS expression.

Overexpression or Down-Regulation of Tristetraprolin Modulates Human iNOS mRNA Stability but Does Not Change Human iNOS Promoter Activity. To test whether the effects of enhancement or reduction of tristetraprolin expression on iNOS expression resulted from tristetraprolin-mediated changes in the stability of the human iNOS mRNA, we performed actinomycin D experiments. DLD-1-pZeo, -pZeo-TTP-sense, and -pZeo-TTP-antisense cells were incubated with CM for 6 h. Then actinomycin D (10 μg/ml) was added to stop transcription, and RNA was isolated after 0, 2, 4, 6, and 18 h. Expression of iNOS mRNA in comparison with GAPDH was determined by qRT-PCR. As shown in Fig. 6A, compared with pZeo cells (t1/2 = 3.95 ± 0.24 h), overexpression of tristetraprolin resulted in nearly a 2-fold enhancement of human iNOS mRNA stability (t1/2 = 6.76 ± 0.64 h). Therefore, down-regulation of tristetraprolin expression reduced iNOS mRNA stability (t1/2 = 3.12 ± 0.16 h).

Several RNA-binding proteins have been described to bind to DNA and regulate promoter activity, too (He et al., 2000; Fiset and Chabot, 2001; Katahira et al., 2001; Donev et al., 2002). Therefore, we analyzed whether enhancement or reduction of tristetraprolin expression changes human iNOS promoter activity. We transiently transfected pNOS2(16)Luc and pRL-SV40 (a construct containing R. reniformis luciferase, for normalization of transfection efficiency) into DLD-1-pZeo, DLD-1-pZeo-hTTPs, and DLD-1-pZeo-hTTPas cells. After transfection, the cells were incubated in the presence or absence of the cytokine mixture and firefly and R. reniformis luciferase activity were analyzed in extracts of these cells. As shown in Fig. 6B, cytokine incubation resulted in similar enhancement (approximately 3-fold) of iNOS promoter activity in all three cell lines. Therefore, the effect of tristetraprolin on iNOS expression is unlikely to involve regulation of human iNOS promoter activity. In summary, the enhancing effect of tristetraprolin overexpression on human iNOS mRNA expression results from enhanced mRNA stability.

Tristetraprolin Does Not Interact with the Human iNOS mRNA. To analyze the interaction of tristetraprolin with the human iNOS mRNA 3′-UTR, we purified recombinant GST-TTP protein for UV cross-linking experiments. Purified GST-TTP and GST protein (as negative control) was incubated with labeled transcripts comprising the human iNOS 3′-UTR sequence, and tristetraprolin/RNA complex formation was assayed by UV cross-linking. As shown in Fig. 7A, we detected no complex formation between recombinant GST-TTP-protein and the whole 3′-UTR transcript. In contrast, as shown before by RNA gel shift experiments (Rodriguez-Pascual et al., 2000), GST-HuR specifically binds to the human iNOS 3′-UTR sequence. Then, we analyzed the interaction of GST-TTP with the human iNOS 5′-UTR and the human iNOS coding sequence. GST-TTP did not interact with one of these iNOS mRNA fragments (Fig. 7B). However, using a human c-fos 3′-UTR RNA, a known target for tristetraprolin binding, instead of human iNOS mRNA fragments, resulted in a specific tristetraprolin/RNA complex formation (Fig. 7C). These experiments demonstrated that tristetraprolin does not bind to any region of the human iNOS mRNA.

Tristetraprolin Interacts with the KSRP in Human DLD-1 Cells. The experiments above showed post-transcriptional regulation of cytokine-induced iNOS expression by tristetraprolin without binding of tristetraprolin to the iNOS
Fig. 4. Overexpression of tristetraprolin enhances and down-regulation of tristetraprolin expression reduces cytokine-induced iNOS expression. DLD-1 cells were stably transfected with eukaryotic expression vectors containing a tristetraprolin-HA cDNA in either sense (pZeo-hTTPs) or antisense (pZeo-hTTPas) orientation. Pools of cells were tested for tristetraprolin expression or for cytokine-induced iNOS mRNA in comparison with DLD-1 cells stably transfected with the empty expression vector pZeoSV2 (pZeo). For analysis of iNOS expression, the cells were preincubated for 18 h in medium without FCS and phenol red before being exposed to CM for the time periods indicated. A, analysis of tristetraprolin protein expression in cytoplasmic extracts from untreated DLD-1, pZeo, pZeo-hTTPs, and pZeo-hTTPas cells by Western blot using polyclonal anti-tristetraprolin and monoclonal β-tubulin antibodies. This blot is representative of three other blots showing similar results. Densitometric analyses of these blots revealed the following relative levels of TTP protein expression (mean ± S.E.M.): pZeo, 100.00 ± 0.00; pZeo-hTTPs, 171.00 ± 6.93; pZeo-hTTPas, 65.89 ± 5.82. B, representative RNase protection experiment detecting iNOS and GAPDH mRNA expression in pZeo-hTTPs and pZeo cells. Experiments were performed using antisense RNA probes for human iNOS and GAPDH mRNA (for normalization). The positions of the protected iNOS- and GAPDH fragments are indicated. N, human iNOS probe; T, tRNA control; M, molecular weight standard, φX174-restricted with HinfI; co, RNA from cells incubated in medium without FCS only. C, summary of densitometric analyses of seven different gels and four qRT-PCR analyses using RNA isolated from stably transfected DLD-1-pZeo or pZeo-hTTPs cells. Data (means ± S.E.M.) represent relative iNOS mRNA levels (*, p < 0.05; ***, p < 0.001; ns, not significant versus pZeo cells incubated for 4 h with CM). D, representative RNase protection experiment detecting iNOS and GAPDH mRNA expression in pZeo-hTTPas and pZeo cells. Experiments were performed using antisense RNA probes for human iNOS and GAPDH mRNA (used for normalization). The positions of the protected iNOS and GAPDH fragments are indicated. N, human iNOS probe; T, tRNA control; M,
mRNA. Therefore, it seems very likely that tristetraprolin interacts with other proteins important for the stability of iNOS mRNA. KSRP has been shown to be an essential component of the degradation machinery of mRNAs containing AREs (Chen et al., 2001; Gherzi et al., 2004). Therefore, we tested the interaction of tristetraprolin and KSRP by coimmunoprecipitation experiments. Cellular extracts from CM or untreated DLD-1 cells were incubated with polyclonal anti-tristetraprolin antibodies or with a rabbit preimmune serum as negative control. The immunoprecipitated material was analyzed by Western Blotting, using a monoclonal anti-KSRP antibody. As shown in Fig. 8A, tristetraprolin displayed a marked protein-protein interaction with KSRP. This interaction was enhanced by cytokine-incubation. To analyze the effect of SB203580 on this tristetraprolin-KSRP interaction, cellular extracts from CM or untreated DLD-1 cells pretreated with or without 10 μM were incubated with monochlonal anti-KSRP antibodies or with a rabbit preimmune serum as negative control. As shown in Fig. 8, B and C, immunoprecipitation with monochlonal anti-KSRP antibodies and Western blotting of the precipitates with polyclonal anti-tristetraprolin antibodies revealed the same tristetraprolin-KSRP protein-protein interaction. As shown above, this interaction was enhanced by cytokine treatment. SB203580 treatment reduced this cytokine enhancement.

**Discussion**

Gene expression is controlled by both transcriptional and post-transcriptional mechanisms. A central part of the

---

**Fig. 5.** Down-regulation of tristetraprolin expression by siRNA reduces cytokine-induced iNOS mRNA expression. A549/8 cells were stably transfected with psiRNA-hH1-GFPpZeo-TTP. In these cells, siRNAs containing a hairpin structure (shRNAs) were generated and were directed against the human tristetraprolin mRNA. Stable transfectants were selected for Zeocin resistance and GFP expression. As a control, A549/8 cells stably transfected with the empty psiRNA-hH1-GFPpZeo vector were generated as well. The cells were preincubated for 18h in medium without FCS and phenol red before being exposed to cytokines (CM) for 6h. Then, total RNA or protein extracts were prepared. A, summary of four qRT-PCR analyses using RNA isolated from stably transfected A549/8-psiRNA-hH1-GFPpZeo-TTP (siTTP) or psiRNA-hH1-GFPpZeo (GFP) cells. Data (means ± S.E.M.) represent relative tristetraprolin mRNA levels (*, p < 0.05; **, p < 0.01; versus psiRNA-hH1-GFPpZeo cells incubated for 6h with CM). B, analysis of tristetraprolin and β-tubulin protein expression in A549/8-psiRNA-hH1-GFPpZeo-TTP (siTTP) or psiRNA-hH1-GFPpZeo (GFP) cells by Western Blot using polyclonal anti-tristetraprolin- and monoclonal β-tubulin antibodies and cytoplasmic extracts from stably transfected A549/8 cells. The position of β-tubulin and tristetraprolin is indicated. This blot is representative of three other blots showing similar results. C, statistical analysis of five qRT-PCR analyses using RNA isolated from stably transfected A549/8-psiRNA-hH1-GFPpZeo-TTP (siTTP) or psiRNA-hH1-GFPpZeo (GFP) cells. Data (means ± S.E.M.) represent relative iNOS mRNA levels (***, p < 0.001 versus psiRNA-hH1-GFPpZeo cells incubated for 6h with CM).
post-transcriptional modulation of gene expression is mediated by regulation of mRNA stability. The stability may vary considerably from one mRNA to another and can be modulated by various extracellular stimuli (Wilusz et al., 2001). A tight control of mRNA stability enables cells to fine-tune the expression of genes, permits rapid changes in the levels of mRNAs, and provides a mechanism for prompt termination of protein production. The rate of mRNA decay is determined by cis-acting sequences within the mRNA that are recognized by trans-acting factors. Dysregulation of the expression of RNA-binding proteins or mutation of important cis-acting binding sequences and thereby dysregulation of mRNA

![Graph showing mRNA stability and decay rates](image)

**Fig. 6.** Effect of tristetraprolin expression on human iNOS mRNA stability and iNOS promoter activity. A, DLD-1-pZeo control cells (pZeo), DLD-1-pZeo-hTTPs cells (pZeo-hTTPs), or DLD-1-pZeo-hTTPas cells (pZeo-hTTPas) were incubated with a cytokine mixture for 6 h. Then, 10 μM actinomycin D was added, and RNAs were prepared after 0 to 18 h. iNOS mRNA and GAPDH mRNA concentrations were determined by qRT-PCR, and iNOS mRNA was normalized to GAPDH mRNA. A summary of six qRT-PCR analyses is shown. Data (means ± S.E.M.) represent relative iNOS mRNA levels (*, p < 0.05; **, p < 0.01; ns, not significant versus 0 h actinomycin D). Curve-fitting was performed using GraphPad Prism for Macintosh. B, DLD-1-pZeo control cells (pZeo, black columns), DLD-1-pZeo-hTTPs cells (pZeo-hTTPs, hatched columns), or DLD-1-pZeo-hTTPas cells (pZeo-hTTPas, gray columns) were transfected with a luciferase reporter gene under the control of the 16-kb human iNOS promoter. After transfection, cells were incubated with or without a mixture of cytokines (CM) for 8 h. Columns (mean ± S.E.M.) represent the cytokine-induced activation of the iNOS promoter expressed as a percentage of the corresponding basal values determined in the absence of cytokines (**, p < 0.01; ***, p < 0.001; ns, not significant versus control cells).

![Recombinant protein binding assay](image)

**Fig. 7.** Recombinant tristetraprolin protein does not bind to the human iNOS mRNA. Several 32P-radiolaabeled RNA transcripts were incubated with 0.6 μg of purified bovine serum albumin (BSA), GST, GST-HuR (HuR), or GST-TTP (TTP) fusion protein. The radiolabeled RNAs were synthesized from plasmids containing the human iNOS 3'-UTR, iNOS 5'-UTR, or iNOS coding sequence (cds). As a control, radiolaabeled c-fos-3'-UTR RNA was also included. The positions of RNA/protein complexes are indicated.
clonal anti-tristetraprolin antibodies (WB: α-TTP) or a preimmune serum (IP: PreIS). Coprecipitation of KSRP was analyzed by performing Western Blots using monoclonal anti-KSRP antibodies (WB: α-KSRP). The presence of the KSRP protein is indicated. One representative of three coimmunoprecipitation analyses is shown. B, RNase pretreated cell lysates were subjected to immunoprecipitation using monoclonal anti-KSRP antibodies (IP: α-KSRP) or a preimmune serum (IP: PreIS). Coprecipitation of KSRP was analyzed by performing Western Blots using monoclonal anti-KSRP antibodies (WB: α-KSRP) or a preimmune serum (WB: PreIS). Coprecipitation of tristetraprolin was analyzed by performing Western blots using polyclonal anti-tristetraprolin antibodies (WB: α-TTP). The presence of the tristetraprolin protein (TTP) and of the immunoglobulin heavy chain (hc) is indicated. One representative of three coimmunoprecipitation analyses is shown. C, to normalize for precipitated KSRP protein of the experiment (Fig. 8B), the amount of KSRP protein was analyzed performing Western Blots using monoclonal anti-KSRP antibodies (WB: α-KSRP). As control, KSRP expression was analyzed in the extract from untreated DLD-1 cells (5% of the extract input, In). The presence of the KSRP protein is indicated. One representative of three coimmunoprecipitation analyses is shown. D, to analyze the effect of inhibition of p38 MAPK on the human iNOS promoter activity and iNOS mRNA and protein expression in parallel, we used DLD-1 cells stably transfected with pNOS2(16)Luc [containing a 16-kb fragment of the human iNOS promoter (GenBank accession no. AC005697)]. RNase protection experiments and quantitative real time RT-PCR (Fig. 1A–C and E), Western blots (Fig. 1D), nitrite measurements (Fig. 1E), and luciferase activity determination (data not shown) revealed that inhibition of p38 MAPK by SB203580 or a dominant-negative p38 MAPK isoform reduced iNOS mRNA and protein expression but not luciferase mRNA or protein expression. This effect of p38 MAPK inhibition on iNOS expression has been shown in human osteoarthritic chondrocytes (Poljakovic et al., 2003) and human kidney epithelial cells (Martel-Pelletier et al., 1999). In transient transfection experiments using fragments of the human or rat iNOS promoter (GenBank accession no. AC005697) and the tristetraprolin family of zinc-finger RNA binding proteins (Lai et al., 1999).

Stability has been associated with different diseases such as chronic inflammatory diseases (Kontoyiannis et al., 1999), cancer (Gouble et al., 2002), and Alzheimer’s disease (Hollams et al., 2002).

The best-characterized cis-acting sequences responsible for mRNA decay in mammalian cells are the AU-rich elements (AREs) present within the 3′-untranslated regions (3′-UTRs) of short-lived mRNAs from cytokine, proto-oncogene and growth-factor genes, whose expression has to be regulated exactly (Bakheet et al., 2001). These AREs are involved in deadenylation and subsequent degradation of mRNAs (Shyu et al., 1991) and have also been described to stimulate 5′-decapping (Gao et al., 2001). More than 15 proteins are known to bind to AREs (Hollams et al., 2002). Only few of them have been shown clearly to regulate mRNA stability. These include the AU-rich element RNA-binding protein 1 (AUF1) (Zhang et al., 1993), the embryonic lethal abnormal vision (ELAV) proteins (also named Hu proteins), especially HuR (Brennan and Steitz, 2001), KSRP (Chen et al., 2001), and the tristetraprolin family of zinc-finger RNA binding proteins (Lai et al., 1999).

One important signal transduction pathway involved in the regulation of ARE-mRNA degradation is the p38 MAPK pathway (Kracht and Saklatvala, 2002). Inhibition of p38 MAPK by either pharmacological inhibitors or overexpression of dominant-negative p38 MAPK isoforms results in enhanced degradation of different ARE-containing mRNAs, such as the cyclooxygenase-2 mRNA (Ridley et al., 1998), the IL-1β mRNA (Kracht and Saklatvala, 2002), the TNF-α mRNA (Mahtani et al., 2001), and the iNOS mRNA (Lui et al., 2004).

To analyze the effect of inhibition of p38 MAPK on the human iNOS promoter activity and iNOS mRNA and protein expression in parallel, we used DLD-1 cells stably transfected with pNOS2(16)Luc [containing a 16-kb fragment of the human iNOS promoter (GenBank accession no. AC005697)]. RNase protection experiments and quantitative real time RT-PCR (Fig. 1A–C and E), Western blots (Fig. 1D), nitrite measurements (Fig. 1E), and luciferase activity determination (data not shown) revealed that inhibition of p38 MAPK by SB203580 or a dominant-negative p38 MAPK isoform reduced iNOS mRNA and protein expression but not luciferase mRNA or protein expression. This effect of p38 MAPK inhibition on iNOS expression has been shown in human osteoarthritic chondrocytes (Poljakovic et al., 2003) and human kidney epithelial cells (Martel-Pelletier et al., 1999). In transient transfection experiments using fragments of the human or rat iNOS promoter, reduction of lipopoly saccharide and/or cytokine-induced promoter activity by p38 MAPK inhibition on iNOS expression has been shown in human osteoarthritic chondrocytes (Poljakovic et al., 2003) and human kidney epithelial cells (Martel-Pelletier et al., 1999). In transient transfection experiments using fragments of the human or rat iNOS promoter, reduction of lipopoly saccharide and/or cytokine-induced promoter activity by p38 MAPK inhibition on iNOS expression has been shown in human osteoarthritic chondrocytes (Poljakovic et al., 2003) and human kidney epithelial cells (Martel-Pelletier et al., 1999).
p38 MAPK seems to regulate human iNOS expression at the post-transcriptional level.

The exact mechanism of p38 MAPK-mediated stabilization of ARE-containing mRNAs is not known. p38 MAPK was found to control the expression and post-translational modification of tristetraprolin either directly (Carballo et al., 2001) or via its substrate MAPKAP-K2/2MK2 (Tchen et al., 2004), suggesting that the p38 MAPK-mediated stabilization of ARE-mRNAs may work, at least in part, by modulating tristetraprolin expression/activity.

In an attempt to further characterize the involvement of tristetraprolin in human iNOS expression, we analyzed the effect of cytokine-incubation on expression of tristetraprolin in DLD-1 cells. As shown in Fig. 2, CM incubation enhanced tristetraprolin mRNA (Fig. 2, A and B) and protein (Fig. 2C) expression. The time curve of tristetraprolin induction was similar to the time curve of human iNOS induction in these cells (Rodriguez-Pascual et al., 2000). Because cytokine-induced expression of iNOS is reduced by SB203580-treatment, we then analyzed whether this treatment also influences tristetraprolin expression. As shown in Fig. 3, preincubation with 10 μM SB203580 decreased tristetraprolin expression. A similar effect of p38 MAPK inhibition had been described in murine RAW macrophages (Tchen et al., 2004).

Because tristetraprolin seemed to be a good candidate for an ARE-binding protein modulating human iNOS expression, we stably transfected human DLD-1 cells with an eukaryotic expression vector coding for a HA-tagged tristetraprolin protein. To down-regulate endogenous tristetraprolin expression, cells containing the tristetraprolin-HA cDNA in an opposite orientation were generated as well. Pools of clones were analyzed for cytokine-induced iNOS expression. As shown in Fig. 4, overexpression of HA-tagged tristetraprolin protein (pZeo-hTTPs) unexpectedly resulted in enhanced cytokine-induced iNOS mRNA expression (Fig. 4, B and C) and NO production (Fig. 4F) compared with control cells stably transfected with the expression vector (pZeo). Therefore, transfection of the antisense construct (pZeo-hTTPas) resulted in reduced iNOS mRNA (Fig. 4, D and E) and NO production (Fig. 4F).

Because the stabilizing effect of tristetraprolin on iNOS expression in DLD-1 cells was highly unexpected, we decided to expand this analysis using another cell line and a different method to modulate tristetraprolin expression. We generated A549/8 cells (siTTP) stably transfected with a vector (psiRNA-hH1-GFP-pZeo-TTP) coding for siRNAs directed against the human tristetraprolin mRNA. As control, A549/8 cells pools transfected with the empty vector (GFP) were generated. By using the siRNA technique, we were able to down-regulate tristetraprolin mRNA and protein expression (Fig. 5, A and B) in A549/8 cells. As shown in DLD-1 cells and A549/8 cells, down-regulation of tristetraprolin expression resulted in reduction of cytokine-induced iNOS mRNA expression (see Fig. 5C). Therefore, in contrast to its described destabilizing activity (Blackshear, 2002), tristetraprolin seems to be positively involved in cytokine-induced iNOS expression in human epithelial cells.

To analyze the effect of the modulation of tristetraprolin expression on human iNOS mRNA stability, actinomycin D experiments were performed with the three different stably transfected DLD-1 cell pools (pZeo, pZeo-hTTPs, and pZeo-hTTPas). These experiments (Fig. 6A) showed that tristetraprolin overexpression (pZeo-hTTPs cells) enhanced whereas tristetraprolin down-regulation (pZeo-hTTPas cells) decreased iNOS mRNA stability compared with cells transfected with the expression vector (pZeo cells). Therefore, tristetraprolin-mediated modulation of human iNOS expression is likely to result from post-transcriptional effects of tristetraprolin.

Some RNA-binding proteins, such as AUF1 or heteronuclear ribonucleoprotein A1, have been described to also display DNA-binding activity and to regulate the promoter activity of different genes (Fuentes-Panana et al., 2000; Shen and Masters, 2001). To exclude the possibility that the tristetraprolin-mediated effects on human iNOS expression also resulted from regulation of human iNOS promoter activity by tristetraprolin, we transiently transfected the plasmid pNOS2(16)Luc into the three different cell pools (pZeo, pZeo-hTTPs, and pZeo-hTTPas) and determined luciferase activity after cytokine-induction. As shown in Fig. 6B, modulation of tristetraprolin expression in DLD-1 cells did not result in changes of cytokine-induced human iNOS promoter activity.

The 3'-UTR of the human iNOS contains five AREs, two of which had been shown to interact with the mRNA stabilizing factor HuR (Rodriguez-Pascual et al., 2000). Therefore, we analyzed the exact binding site of tristetraprolin in the human iNOS 3'-UTR sequences. We were surprised to find that, as shown in Fig. 7, A and B, UV cross-linking experiments indicated that recombinant GST-TTP protein did not interact with any region of the human iNOS mRNA (3'-UTR, 5'-UTR, cds). However, the same GST-TTP protein was able to bind to the c-fos-3'-UTR, a known target of tristetraprolin (Fig. 7C), and to the human TNF-α 3'-UTR (data not shown). Therefore, tristetraprolin does not seem to interact with the human iNOS mRNA.

The results shown above indicate an indirect stimulatory effect of tristetraprolin on human iNOS expression. Lai et al. (2002) also reported that tristetraprolin mutants without RNA binding activity enhanced the stability of ARE-containing mRNAs such as the TNF-α transcript. This unexpected effect of mutant tristetraprolin seems to be based on an interaction of these proteins with enzymes stimulating the degradation of ARE-containing mRNAs (Lai et al., 2002). Supporting this hypothesis, Chen et al. (2001) showed tristetraprolin- and KSRP-dependent ARE-mRNA degradation activity of the human exosome. The purified exosome, a complex of exonucleases catalyzing the 3'→5' decay pathway of mRNAs, was unable to bind to and degrade ARE-containing mRNAs. However, ARE-binding proteins such as KSRP and tristetraprolin recruited the exosome to these mRNAs and enabled degradation (Chen et al., 2001; Gherzi et al., 2004). Therefore, we analyzed the interaction of tristetraprolin with KSRP in human DLD-1 cells. As shown in Fig. 8, A and B, tristetraprolin displayed a protein-protein interaction with KSRP, which was enhanced by cytokine treatment. As shown in Fig. 8B, the cytokine enhancement of the tristetraprolin-KSRP interaction was reduced by SB203580-treatment.

KSRP markedly destabilized human iNOS mRNA and overexpression of KSRP down-regulated human iNOS expression (K. Linker, A. Pautz, M. Fechir, and H. Kleinert, submitted). Therefore, without binding of tristetraprolin to the human iNOS mRNA, the enhanced expression of tristetraprolin after cytokine treatment and the cytokine-enhanced interaction of tristetraprolin with KSRP seems to result in a
dislodgement of the KSRP-exosome complex from the human iNOS mRNA. Thereby, enhanced tristetraprolin expression in cytokine-treated cells seems to stabilize iNOS mRNA and thus enhances iNOS expression. SB203580-mediated inhibition of the p38 MAPK pathway reduced the enhancement of tristetraprolin expression by cytokines and thereby destabilized iNOS mRNA.

In conclusion, our data support the following mechanism. Cytokines required for iNOS induction also enhance tristetraprolin expression, most likely by p38 MAPK activation. The elevated tristetraprolin protein in turn reduces the recruitment of exosomes to the human iNOS mRNA by enhanced interaction with KSRP. The reduced ability of the exosome to bind to and degrade the human iNOS mRNA results in an enhanced iNOS mRNA stability. This leads to a higher iNOS protein expression and an increase of iNOS-dependent NO production.

Acknowledgments

We thank Dr. P. Blackshear for providing the plasmid pCMV-hTTP-Flag and Dr. H. Holtmann for providing the plasmid pCS3-dependent NO production. Bhat NR, Feinstein DL, Shen Q, and Bhat AN (2002) p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells. J Biol Chem 277:29584–29592.


References


TTP Regulates Human iNOS Expression 2161


Address correspondence to: Dr. Hartmut Kleinert, Department of Pharmacology, Johannes Gutenberg University, Obere Zahlbacher Str. 67, 55101 Mainz, Germany. E-mail: kleinert@mail.uni-mainz.de

[At ASPET Journals on March 1, 2017 molpharm.aspetjournals.org Downloaded from]